Procalcitonin - potential, limitations and availability by VLADIMIRA RIMAC
84   |  SIGNA VITAE
Procalcitonin - potential, limitations and availability
VLADIMIRA RIMAC
Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia
Corresponding author:  
Vladimira Rimac
University Hospital Centre Zagreb
Kispatićeva 12, 10000 Zagreb
e-mail: kutnjakvl@gmail.com
ABSTRACT
Bacterial infections and sepsis are major 
problems in critically ill patients. Timely 
diagnosis and therapy reduce morbidity 
and mortality. Many studies have included 
the investigation of various biomarkers 
whose elevated concentrations can indi-
cate sepsis; among them, PCT proved to be 
most useful.
PCT is synthesized in the thyroid gland 
as a prohormone of calcitonin. In healthy 
individuals the PCT concentration is <0.1 
ng/mL.
The advantage of the PCT is a high nega-
tive predictive value for the exclusion of 
sepsis, with the cut-off value of 0.5 ng/ml. 
A concentration between 2 and 10 ng/ml 
indicates strong sepsis, whereas a value 
≥10 ng/ml is associated with septic shock. 
In addition to the diagnosis of sepsis, the 
measurement of PCT concentration is use-
ful for the introduction and monitoring of 
antibiotic therapy, which is performed ac-
cording to an algorithm based on the cut-
off value for PCT.
Immunoassays are used to measure PCT 
concentrations in serum or plasma. It is 
possible to determine the concentration in 
whole blood by using point-of-care testing.
In pathological conditions that are not 
associated with sepsis, PCT is useful as a 
prognostic indicator of disease complica-
tions. Some studies suggest that PCT is a 
potential early indicator of acute coronary 
syndrome.
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INTRODUCTION
Bacterial infections and sepsis are major 
problems in critically ill patients, par-
ticularly those in intensive care units. 
The timely diagnosis and introduction 
of therapy reduces related morbidity and 
mortality. Most of the biomarkers rou-
tinely used for the diagnosis of sepsis (e.g., 
C-reactive protein (CRP), white blood 
cell count) are not specific and sensitive 
for the early detection of sepsis. For years, 
various studies have been searching for a 
potential biomarker for the diagnosis of 
sepsis. Characteristics of a good biomarker 
for sepsis include short half-life, a specific 
increase of the concentration in sepsis and 
concentration decrease during treatment 
with appropriate antibiotic therapy. Stud-
ies have included investigations of various 
cytokines (1), copeptin (2), atrial natri-
uetic peptide (ANP) and the pro-ANP (3), 
but the best characteristics as a potential 
biomarker for the diagnosis of sepsis were 
shown by procalcitonin (PCT).
In 1993, the first study was published that 
showed that high concentrations of PCT 
are present in patients with bacterial infec-
tion and sepsis. (4)
Biochemical characteristics of procalci-
tonin
PCT is a peptide composed of 116 amino 
acids. Physiologically, it is synthesized in 
the C cells of the thyroid gland as a pro-
hormone of calcitonin (calcitonin is a 
hormone that plays a role in calcium ho-
meostasis). In addition, a low PCT con-
centration is produced in neuroendocrine 
cells of the lung and small intestine. In 
physiological conditions, PCT is secreted 
in very small concentrations, and its con-
centration in healthy individuals is <0.1 
ng/mL. (5) Increased secretion of PCT is 
stimulated by inflammatory cytokines, 
bacterial endotoxin and bacterial lipopol-
ysaccharides from certain organs (liver, 
kidney and lungs). (6) Depending on the 
severity of bacterial infection, the concen-
tration can rise up to 1,000-fold than that 
found in healthy individuals. PCT half-
life is approximately 22-26 hours. After 
stimulation, concentration in blood rises 
within 2-4 hours, and the maximum con-
centration is achieved within 6-12 hours. 
These characteristics give it a significant 
advantage over CRP, whose concentration 
in the blood starts to rise 6-10 hours after 
stimulation. In addition to increased con-
centration in bacterial infection, elevated 
CRP concentrations are also found in viral 
infections and in all conditions associated 
with inflammation. 
WHY IS IT NECESSARY TO DETER-
MINE PCT CONCENTRATION?
It is necessary primarily in order to detect 
sepsis at a very early stage, and to monitor 
antibiotic therapy (to check if therapy is ef-
fective and when it can be discontinued).
The defined cut-off for exclusion of bacte-
rial infection and sepsis is the PCT con-
centration of ≤0.2 ng/mL, whereas values 
exceeding 0.5 ng/ml suggest that sepsis is 
possible. (7) The concentrations of PCT ≥2 
and ≤10 ng/ml indicate severe sepsis, while 
the value of ≥10 ng/mL is associated with 
septic shock. SIRS (systemic inflammatory 
response syndrome) and MODS (multi-
ple organ dysfunction syndrome) can also 
be followed by elevated concentrations of 
PCT, but they are usually lower than in 
sepsis, while local bacterial infection usu-
ally does not cause an increased PCT con-
centration. 
Microbiological methods are still the gold 
standard for determining the cause of bac-
terial infection and sepsis. A drawback of 
this method is the time required for analy-
sis results. When there is a possibility of 
sepsis, it is necessary to use a biomarker 
that will either confirm the diagnosis or 
reject it. Procalcitonin is a biomarker that 
possesses such capability because we can 
safely determine whether sepsis is present 
or not based on its measured concentra-
tion. Results of some studies indicate the 
possibility of differentiating Gram-positive 
bacterial infection from Gram-negative us-
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ing the concentration of PCT. In actuality, 
PCT concentration is higher in infections 
with Gram-negative bacteria compared to 
infection with Gram-positive bacteria. (8)
As stated above, in addition to diagnosis, 
measuring the concentration of PCT is 
useful for the introduction and monitoring 
of antibiotic therapy. Monitoring of thera-
py is performed according to an algorithm 
based on the cut-off values for PCT. (9)
THE ROLE OF THE CLINICAL LABORA-
TORY IN THE DIAGNOSIS OF SEPSIS 
- HOW WE CAN DETERMINE THE CON-
CENTRATION OF PROCALCITONIN
The concentration of PCT can be meas-
ured in serum and plasma (EDTA or hepa-
rin). As PCT is a biomarker whose con-
centration is necessary to be determined as 
quickly as possible, the use of plasma is rec-
ommended because it has advantages over 
serum in terms of preanalytical require-
ments (a plasma sample can be centrifuged 
immediately after blood sampling, which 
significantly reduces the turnaround time).
The first assays to determine the concen-
tration of PCT were based on manual im-
munochemistry methods (Brahms PCT 
LIA). (10) Assays which are used to deter-
mine the concentration of PCT are based 
on an immunochemical reaction (antigen-
antibody reaction). A type of immuno-
chemical reaction is a sandwich ELISA, 
which is based on the formation of an 
antibody-procalcitonin-antibody complex. 
All assays for the determination of PCT 
concentrations are standardized accord-
ing to the BRAHMS PCT LIA assay, but 
are adapted for use on different analysers 
(table 1). A comparison of results obtained 
by different assays shows good correlation. 
(10) In addition to tests which are used on 
biochemical analysers in clinical labora-
tories, PCT concentrations can be deter-
mined using point-of-care tests (POCT) 
(Brahms PCT-Q assay). (11) These assays 
are semi-quantitative and use whole blood 
for analysis, with results that are available 
in less than 30 minutes. A limitation of 
POCT is that these tests are unable to pre-
cisely monitor changes in PCT concentra-
tion trends, which is needed to monitor a 
patient’s clinical status.
IS PCT CONCENTRATION DETERMI-
NATION CLINICALLY SIGNIFICANT IN 
OTHER PATHOLOGICAL CONDITIONS 
NOT RELATED TO SEPSIS?
Many studies have investigated the signifi-
cance of determining the concentration of 
PCT in various types of inflammation that 
are not associated with sepsis, or the pos-
sible benefit of determining the concentra-
tion of PCT in infections without sepsis. 
In acute pancreatitis, the significance of 
determining PCT levels is limited; PCT is 
useful as a prognostic indicator of disease 
complications and adverse outcomes. (16) 
The usefulness of PCT in urinary tract in-
fections involves the exclusion of bacterial 
diseases with a cut-off value of 0.25 µg/L 
(0.25 ng/ml) (17). With the PCT cut-off 
value of 0.1 (0.25) ng/ml, it is possible to 
differentiate patients with septic and non-
septic arthritis. (18) The role of procalci-
tonin is investigated in pathogenesis of 
atherosclerosis and myocardial infarction 
as a possible early marker of acute coro-
nary syndrome. (19)
CONCLUSION
Procalcitonin as a biomarker for bacterial 
infections and sepsis has advantages over 
those biomarkers used in routine practice 
as it can be detected early in the blood. The 
concentration of PCT increases within 2-4 
hours in bacterial infections. Concentra-
tions of less than 0.5 ng/ml have a high 
negative predictive value for the exclusion 
of sepsis. Regardless of the increase in the 
concentration of PCT in some infections 
not associated with sepsis, it is certain that 
a value of >2 ng/mL indicates sepsis and a 
value exceeding 10 ng/mL indicates septic 
shock. It has been shown that PCT deter-
mination is also important for monitoring 
antibiotic therapy where a significant de-
crease in PCT concentration indicates un-
necessary use of antibiotics therapy. 
Table 1.  Comparison of PCT immunoassays (11-14).
Sample volume 
(µL)
Duration of analysis 
(min)




ADVIA Centaur B·R·A·H·M·S PCT 100 29 0.02 - 75 <0.02
B·R·A·H·M·S PCT sensitive KRYPTOR 50 19 0.02 – 50 <0.02
VIDAS® B·R·A·H·M·S PCT 200 20 0,05 – 200 <0.05
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